Effects of pioglitazone on cardiac ion currents and action potential morphology in canine ventricular myocytes

European Journal of Pharmacology

Volumn 710, Issue 1-3, 2013, Pages 10-19

  Kistamás, Kornél ^a   Szentandrássy, Norbert ^a   Hegyi, Bence ^a   Ruzsnavszky, Ferenc ^a   Váczi, Krisztina ^a   Bárándi, László ^a   Horváth, Balázs ^a   Szebeni, Andrea ^b   Magyar, János ^a   Bányász, Tamás ^a   Kecskeméti, Valéria ^b   Nánási, Péter P ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Action potentials; Antidiabetic agents; Dog cardiomyocytes; Ion currents; Pioglitazone

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; LEMAKALIM; PIOGLITAZONE; POTASSIUM ION;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG EFFECT; FEMALE; HEART DEPOLARIZATION; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE; ION CURRENT; MALE; MICROELECTRODE; MUSCLE CELL; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; VOLTAGE CLAMP; WHOLE CELL;

ACTION POTENTIALS; ANIMALS; CALCIUM; DOGS; FEMALE; HYPOGLYCEMIC AGENTS; ION CHANNELS; MALE; MYOCYTES, CARDIAC; POTASSIUM; SODIUM; THIAZOLIDINEDIONES;

EID: 84877607501     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.03.047     Document Type: Article

References (48)

1. M. Arikawa, N. Takahashi, T. Kira, M. Hara, T. Saikawa, and T. Sakata Enhanced inhibition of L-type calcium currents by troglitazone in streptozotocin-induced diabetic rat cardiac ventricular myocytes Br. J. Pharmacol. 136 2002 803 810
2. M. Arikawa, N. Takahashi, T. Kira, M. Hara, H. Yoshimatsu, and T. Saikawa Attenuated inhibition of L-type calcium currents by troglitazone in fructose-fed rat cardiac ventricular myocytes J. Cardiovasc. Pharmacol. 44 2004 109 116
3. K. Budde, H.H. Meumayer, L. Fritsche, W. Sulowicz, T. Stompor, and D. Eckland The pharmacokinetics of pioglitazone in patients with impaired renal function Br. J. Clin. Pharmacol. 55 2003 368 374
4. + currents in canine cardiomyocytes: their role in ventricular repolarization Acta Physiol. Scand. 190 2007 189 198
5. J. Berger, P. Bailey, C. Biswas, C.A. Cullinan, T.W. Doebber, N.S. Hayes, R. Saperstein, R.G. Smith, and M.D. Leibowitz Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice Endocrinology 137 1996 4189 41950
6. 2 ligands of the peroxisome proliferator-actvated receptor-γ (PPAR-γ) reduce ischemia/reperfusion injury of the gut Br. J. Pharmacol. 140 2003 366 376
7. J.A. Dormandy, M. Battachaya, and A.R. van Troostenburg de Bruyn Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive Drug Saf. 32 2009 187 202
8. L.S. Doshi, M.K. Brahma, U.A. Bahirat, A.V. Dixit, and K.V. Nemmani Discovery and development of selective PPARgamma modulators as safe and effective antidiabetic agents Expert Opin. Invest. Drugs 19 2010 489 512
9. G.R. DREAM Trial Investigators: Dagenais, H.C. Gerstein, R. Holman, A. Budaj, A. Escalante, T. Hedner, M. Keltai, E. Lonn, S. McFarlane, M. McQueen, K. Teo, P. Sheridan, J. Bosch, J. Pogue, and S. Yusuf Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and pioglitazone Medication (DREAM) trial Diabetes Care 31 2008 1007 1014
10. R. Fischmeister, L.J. DeFelice, R.K. Ayer, R. Levi, and R.L. DeHaan Channel currents during spontaneous action potentials in embryonic chick heart sells. The action potential patch clamp Biophys. J. 46 1984 267 271
11. H.C. Gerstein, S. Yusuf, J. Bosch, J. Pogue, P. Sheridan, N. Dinccag, M. Hanefeld, B. Hoogwerf, M. Laakso, V. Mohan, J. Shaw, B. Zinman, and R.R. Holman Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Lancet 368 2006 1096 1105
12. K. Gima, and Y. Rudy Ionic current basis of electrocardiographic waveforms: a model study Circ. Res. 90 2002 889 896
13. D.J. Graham, R. Ouellet-Hellstrom, T.E. MaCurdy, F. Ali, C. Sholley, C. Worrall, and J.A. Kelman Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone and pioglitazone JAMA 304 2010 411 418
14. M. Hinterseer, B.-M. Beckmann, M. Thomsen, A. Pfeufer, M. Ulbrich, M.F. Sinner, S. Perz, H.E. Wichmann, Cs. Lengyel, R. Schimpf, S.K.G. Maier, A. Varró, M.A. Vos, G. Steinbeck, and S. Kääb Usefulness of short-term variability of QT intervals as a predictor for electrical remodeling and proarrhythmia in patients with nonischemic heart failure Am. J. Cardiol. 106 2010 216 220
15. B.R. Hoffmann, M.F. El-Mansy, D.S. Sem, and A.S. Green Chemical proteomics analysis of off-target bindig profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity J. Med. Chem. 55 2012 8260 8271
16. P.D. Home, S.J. Pocock, H. Beck-Nielsen, R. Gomis, M. Hanefeld, H. Dargie, M. Komajda, J. Gubb, N. Biswas, and N.P. Jones Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol Diabetologia 48 2005 1726 1735
17. Ks to ventricular repolarization in canine myocytes Pflügers Arch. 452 2006 698 706
18. S. Ikeda, and T. Watanabe Effects of troglitazone and pioglitazone on the action potentials and membrane currents of rabbit ventricular myocytes Eur. J. Pharmacol. 357 1998 243 250
19. v4.3 potassium channels by open-channel block and acceleration of closed-state inactivation Br. J. Pharmacol. 163 2011 510 520
20. Ks restricts beat-to-beat variability of repolarization during beta-adrenergic receptor stimulation Mol. Cell. Cardiol. 48 2010 122 130
21. Y. Katohm, S. Hashimoto, J. Kimura, and T. Watanabe Inhibitory action of troglitazone, an insulin-sensitising agent, on the calcium current in cardiac ventricular cells of guinea pig Jpn. J. Pharmacol. 82 2000 102 109
22. S. Kaul, A.F. Bolger, D. Herrington, R.P. Guiliano, and R.H. Eckel Thiazolidinedione drugs and cardiovascular risks. A science advisory from the American Heart Association and American College of Cardiology Foundation Circulation 121 2010 1868 1877
23. S. Kavak, M. Emre, T. Tetiker, T. Kavak, Z. Kolcu, and I. Günay Effects of rosiglitazone on altered electrical left ventricular papillary muscle activities of diabetic rat Naunyn-Schmiedberg's Arch. Pharmacol. 376 2008 415 421
24. A. Krentz Thiazolidinediones: effects of the development and progression of type 2 diabetes and associated vascular complications Diabetes Metab. Res. Rev. 25 2009 112 126
25. Cs. Lengyel, L. Virág, T. Bíró, N. Jost, P. Pacher, J. Magyar, P. Biliczki, V. Kecskeméti, P.P. Nánási, M. Tóth, J.Gy. Papp, and A. Varró Diabetes mellitus attenuates the repolarization reserve in mammalian heart Cardiovasc. Res. 73 2007 512 520
26. Cs. Lengyel, L. Virág, P. Pacher, E. Kocsis, P.P. Nánási, M. Tóth, V. Kecskeméti, J.Gy. Papp, A. Varró, and N. Jost Analysis of the electrophysiological effects of the alloxan induced diabetes mellitus in rabbit heart Acta Physiol. Scand. 192 2008 359 368
27. ATP channels and may increase propensity for ischemic ventricular fibrillation in pigs Diabetologia 51 2008 675 685
28. J. Magyar, Z. Rusznák, P. Szentesi, G. Szucs, and L. Kovács Action potentials and potassium currents in rat ventricular muscle during experimental diabetes J. Mol. Cell. Cardiol. 24 1992 841 853
29. D.K. McGuire, and S.E. Inzucchi New drugs for the treatment of diabetes mellitus. Part I: Thiazolidinediones and their evolving cardiovascular implications Circulation 117 2008 440 449
30. J.P. Morrow, A. Katchman, N.H. Son, C.M. Trent, R. Khan, T. Shiomi, H. Huang, V. Amin, J.M. Lader, C. Vasquez, G.E. Morley, J. D'Armiento, S. Homma, I.J. Goldberg, and S.O. Marx Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias Circulation 124 2011 2812 2821
31. T. Nakajima, K. Iwasawa, H. Oonuma, H. Imuta, H. Hazama, M. Asano, T. Morita, F. Nakamura, J. Suzuki, S. Suzuki, Y. Kawakami, M. Omata, and Y. Okuda Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes Circulation 99 1999 2942 2950
32. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 357 2007 2461 2471
33. C. Piccinini, D. Motola, G. Marchesini, and E. Poluzzi Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting Diabetes Care 34 2011 1369 1371
34. L. Priebe, and D.J. Beuckelmann Simulation study of cellular electric properties in heart failure Circ. Res. 82 1998 1206 1223
35. E. Pueyo, A. Corrias, L. Virág, N. Jost, T. Szél, A. Varró, N. Szentandrássy, P.P. Nánási, K. Burrage, and B. Rodríguez A multiscale investigation of repolarization variability and its role in cardiac arrhythmogenesis Biophys. J. 101 2011 1 11
36. R.E. Ryder Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for optimum management of type 2 diabetes Br. J. Diabetes Vasc. Dis. 11 2011 113 120
37. M. Sarraf, L. Lu, M.J. Reiter, C.R. Greyson, and G.G. Schwartz Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs Cardiovasc. Drugs Ther. 26 2012 195 204
38. N.H. Son, T.S. Park, H. Yamashita, M. Yokoyama, L.A. Huggins, K. Okajima, S. Homma, M.J. Szabolcs, L.S. Huang, and I.J. Goldberg Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice J. Clin. Invest. 117 2007 2791 2801
39. Na in nerve and cardiac membranes Biophys. J. 23 1978 153 156
40. to) in shaping canine ventricular action potential - a dynamic clamp study J. Physiol. 564 2005 411 419
41. G. Szabó, N. Szentandrássy, T. Bíró, I.B. Tóth, G. Czifra, J. Magyar, T. Bányász, A. Varró, L. Kovács, and P.P. Nánási Asymmetrical distribution of ion channels in canine and human left ventricular wall: epicardium versus midmyocardium Pflügers Arch. 450 2005 307 316
42. A. Szebeni, N. Szentandrássy, P. Pacher, J. Simkó, P.P. Nánási, and V. Kecskeméti Can the electrophysiological action of rosiglitazone explain its cardiac side effects? Curr. Med. Chem. 18 2011 3720 3728
43. N. Szentandrássy, T. Bányász, T. Bíró, G. Szabó, I.B. Tóth, J. Magyar, J. Lázár, A. Varró, L. Kovács, and P.P. Nánási Apico-basal inhomogeneity in distribution of ion channels in canine and human ventricular myocardium Cardiovasc. Res. 65 2005 851 860
44. N. Szentandrássy, G. Harmati, L. Bárándi, J. Simkó, B. Horváth, J. Magyar, T. Bányász, I. Lorincz, A. Szebeni, V. Kecskeméti, and P.P. Nánási Effects of rosiglitazone on action potential configuration and ion currents in canine ventricular cells Br. J. Pharmacol. 163 2011 499 509
45. R. Voelker Diabetes drug is linked with bladder cancer risk JAMA 307 2012 2577-2577
46. K.D. Wilson, Z. Li, R. Wagner, P. Yue, P. Tsao, G. Nestorova, M. Huang, D.L. Hirschberg, P.G. Yock, T. Quertermous, and J.C. Wu Trnascriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality PloS One 3 2008 e2609
47. R.L. Winslow, J. Rice, S. Jafri, E. Marban, and B. O'Rourke Mechanism of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: Model studies Circ. Res. 84 1999 571 586
48. D. Xu, N. Murakoshi, M. Igarashi, A. Hirayama, Y. Ito, H. Tada, and K. Aonuma PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model J. Cardiovasc. Electrophysiol. 23 2012 209 217